Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry StudyTessa Straatmijer, Joep Grootjans, Carmen S. Horjus et al.|Clinical Gastroenterology and Hepatology|2022Cited by 51
Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control StudyMaarten te Groen, Frank Hoentjen, Monica E. W. Derks et al.|Clinical Gastroenterology and Hepatology|2022Cited by 18
P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialR Van Linschoten, Frank Hoentjen, Fenna M. Jansen et al.|Journal of Crohn s and Colitis|2023Cited by 0
P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trialMartine Devillers, Frank Hoentjen, L van Lierop et al.|Journal of Crohn s and Colitis|2025Cited by 0
P0396 Combined clinical and histopathological risk stratification for prediction of (severe) endoscopic postoperative recurrence in patients with Crohn’s disease after ileocolic resectionM Bak, Annemarie de Vries, Lindsey Oudijk et al.|Journal of Crohn s and Colitis|2025Cited by 0